Systemic Mastocytoses, Indolent
Oncology·MeSH: Mastocytosis, Systemic
Prevalence
30.0 / 100K
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
Phase 2(1)
| Drug | Company |
|---|---|
| Bezuclastinib | Cogent Biosciences, Inc. (COGT) |
Compare drugs
Frequently asked questions
How many drugs are in development for Systemic Mastocytoses, Indolent?
BioSniper tracks 2 drugs in development for Systemic Mastocytoses, Indolent across 1 company.
How many clinical trials target Systemic Mastocytoses, Indolent?
There are 1 clinical trial targeting Systemic Mastocytoses, Indolent tracked by BioSniper.
What is the prevalence of Systemic Mastocytoses, Indolent?
The estimated prevalence of Systemic Mastocytoses, Indolent is approximately 30.0 per 100,000 population.
Deep-dive into Systemic Mastocytoses, Indolent
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis